Biotech Industry Presses Forward With Latest Transdermal Drug Delivery Advancements

PALM BEACH, Florida, May 3, 2018 /PRNewswire/ --

MarketNewsUpdates.com News Commentary 

The multi-billion dollar Biotech Industry is witnessing a transformation as it relates to the advancement of transdermal drug delivery patches. On the back of factors like rising number of transdermal drug delivery products, enhanced awareness in developed nations about non-invasive way of drug administering drugs into body. After accounting for more than $30 billion in revenues in 2015, the market segment is projected to continue enjoying considerable growth through 2024, according to a report issued by Grand View Research. The market growth is being driven by the increasing occurrence of chronic diseases that have proven to be difficult to treat with traditional oral medications. Additionally, an increasing demand for drug platforms that can be self-administered is another factor influencing the exponential growth of transdermal drug delivery patches. Active biotech companies in the markets this week include Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTC: AQSZF), InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV), InspireMD Inc. (NYSE: NSPR), Baxter International Inc. (NYSE: BAX), Medtronic Plc. (NYSE: MDT).

Aequus Pharmaceuticals Inc. (TSX-V: AQS.V) (OTCQB: AQSZF) BREAKING NEWS: Aequus Pharmaceuticals, a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the Company has received positive feedback from the US Food and Drug Administration ("FDA") on its pre-Investigational New Drug ("pre-IND") submission for the Company's long-acting anti-nausea transdermal patch, AQS1303. Through the pre-IND feedback, the Company has received clear regulatory guidance for AQS1303. The FDA confirmed that the planned Section 505(b)(2) abbreviated regulatory pathway, which allows for the Company to reference safety and efficacy data of the original oral tablet Diclegis®, is appropriate for submission in a New Drug Application ("NDA") for the program in the United States.

"We are very encouraged with the responses from the FDA on our anti-nausea program," said Doug Janzen, Chairman and CEO of Aequus. "The pre-IND feedback met our expectations, confirming our planned clinical program and providing a clear regulatory path forward. The feedback signals positive support for this program and further confirms our overall strategy of improving patient outcomes through alternative delivery methods. We look forward to using this guidance in conjunction with our current development and clinical progress to optimize AQS1303 for success."